<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35285488</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1549-490X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>The oncologist</Title>
          <ISOAbbreviation>Oncologist</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents.</ArticleTitle>
        <Pagination>
          <StartPage>352</StartPage>
          <EndPage>362</EndPage>
          <MedlinePgn>352-362</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/oncolo/oyac047</ELocationID>
        <Abstract>
          <AbstractText>Circulating biomarkers have emerged as valuable surrogates for evaluating disease states in solid malignancies. Their relative ease of access and rapid turnover has bolstered clinical applications in monitoring treatment efficacy and cancer progression. In this review, the roles of various circulating biomarkers in monitoring treatment response are described. Non-specific markers of disease burden, tumor markers (eg CA 125, CEA, PSA, etc.), circulating tumor cells, nucleic acids, exosomes, and metabolomic arrays are highlighted. Specifically, the discovery of each of these markers is reviewed, with examples illustrating their use in influencing treatment decisions, and barriers to their application noted where these exist. Finally, opportunities for future work using these circulating biomarkers are discussed.</AbstractText>
          <CopyrightInformation>© The Author(s) 2022. Published by Oxford University Press.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Janse van Rensburg</LastName>
            <ForeName>Helena J</ForeName>
            <Initials>HJ</Initials>
            <Identifier Source="ORCID">0000-0002-4066-7489</Identifier>
            <AffiliationInfo>
              <Affiliation>Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Spiliopoulou</LastName>
            <ForeName>Pavlina</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siu</LastName>
            <ForeName>Lillian L</ForeName>
            <Initials>LL</Initials>
            <Identifier Source="ORCID">0000-0002-3500-0540</Identifier>
            <AffiliationInfo>
              <Affiliation>Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Oncologist</MedlineTA>
        <NlmUniqueID>9607837</NlmUniqueID>
        <ISSNLinking>1083-7159</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055354" MajorTopicYN="Y">Exosomes</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="Y">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">biomarker</Keyword>
        <Keyword MajorTopicYN="N">ctDNA</Keyword>
        <Keyword MajorTopicYN="N">exosomes</Keyword>
        <Keyword MajorTopicYN="N">metabolomics</Keyword>
        <Keyword MajorTopicYN="N">treatment response</Keyword>
        <Keyword MajorTopicYN="N">tumor marker</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>14</Day>
          <Hour>8</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35285488</ArticleId>
        <ArticleId IdType="pmc">PMC9074993</ArticleId>
        <ArticleId IdType="doi">10.1093/oncolo/oyac047</ArticleId>
        <ArticleId IdType="pii">6548147</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Holdenrieder S, Stieber P.. 
Apoptotic markers in cancer. Clin Biochem. 2004;37:605-617. 10.1016/j.clinbiochem.2004.05.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinbiochem.2004.05.003</ArticleId>
            <ArticleId IdType="pubmed">15234242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Koelink PJ, Lamers CB, Hommes DW, et al. . 
Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer 2009;9:88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2666761</ArticleId>
            <ArticleId IdType="pubmed">19302716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Forkasiewicz A, Dorociak M, Stach K, et al. . 
The usefulness of lactate dehydrogenase measurements in current oncological practice. Cell Mol Biol Lett. 2020:25. 10.1186/s11658-020-00228-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s11658-020-00228-7</ArticleId>
            <ArticleId IdType="pmc">PMC7110762</ArticleId>
            <ArticleId IdType="pubmed">32265995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hoch-Ligeti C.
Effect of irradiation and operation on serum lactic dehydrogenase and glutamic oxalacetic transminase in patients with malignant tumors. Cancer 1962. 10.1002/1097-0142(196207/08)15:4&lt;818::aid-cncr2820150417&gt;3.0.co;2-q.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1097-0142(196207/08)15:4&lt;818::aid-cncr2820150417&gt;3.0.co;2-q</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hsieh KM, Mao SS, Sasananonth K.. 
Serum lactic dehydrogenase activity after excision of transplanted tumors. Cancer Res. 1959;19:700-704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14403583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tasca E, Vassallo E.. 
The lactic dehydrogenase activity in patients with genital neoplasms treated with chemotherapy. Quad Clin Ostet Ginecol 1960;15:285-293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13836987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Arkenau H-T, Olmos D, Ang JE, et al. . 
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer. 2008;98:1029-1033. 10.1038/sj.bjc.6604218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6604218</ArticleId>
            <ArticleId IdType="pmc">PMC2275488</ArticleId>
            <ArticleId IdType="pubmed">18349817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bigot F, Castanon E, Baldini C, et al. . 
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer Oxf Engl 1990 2017;84:212-218.</Citation>
        </Reference>
        <Reference>
          <Citation>
Gershenwald JE, Scolyer RA, Hess KR, et al. . 
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472-492. 10.3322/caac.21409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21409</ArticleId>
            <ArticleId IdType="pmc">PMC5978683</ArticleId>
            <ArticleId IdType="pubmed">29028110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Weeks JC, Yeap BY, Canellos GP, et al. . 
Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol. 1991;9:1196-203. 10.1200/JCO.1991.9.7.1196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.1991.9.7.1196</ArticleId>
            <ArticleId IdType="pubmed">1710656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
William BM, Bongu NR, Bast M, et al. . 
The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma. Rev Bras Hematol E Hemoter. 2013;35:189-191.</Citation>
        </Reference>
        <Reference>
          <Citation>
Tilly H, Dreyling M.. 
Diffuse large B-cell non-Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v172-v174. 10.1093/annonc/mdq203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdq203</ArticleId>
            <ArticleId IdType="pubmed">20555073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Faloppi L, Scartozzi M, Bianconi M, et al. . 
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer 2014;14:110. 10.1186/1471-2407-14-110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-14-110</ArticleId>
            <ArticleId IdType="pmc">PMC3930857</ArticleId>
            <ArticleId IdType="pubmed">24552144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hughes O, Bishop M.. 
Lactate dehydrogenase should be used as marker in testicular tumours. BMJ 1996;313:625. 10.1136/bmj.313.7057.625b.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.313.7057.625b</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jia Z, Zhang J, Wang Z, et al. . 
An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer. Oncotarget 2018;9:10714-10722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5828224</ArticleId>
            <ArticleId IdType="pubmed">29535837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li B, Li C, Guo M, et al. . 
Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC. OncoTargets Ther 2018;11:6287-6294.</Citation>
        </Reference>
        <Reference>
          <Citation>
Egberts F, Kotthoff EM, Gerdes S, et al. . 
Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Eur J Cancer. 2012;48:695-702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21917447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hong J, Yoon H-H, Ahn HK, et al. . 
Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma. Acta Haematol. 2013;130:305-311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24008775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
El-Sharkawi D, Basu S, Ocampo C, et al. . 
Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy. Leuk Lymphoma. 2012;53:1949-1952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22462615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bilici A.
Cytokeratin 18 for chemotherapy efficacy in gastric cancer. Transl Gastrointest Cancer 2015;4:20006-20206.</Citation>
        </Reference>
        <Reference>
          <Citation>
Demiray M, Ulukaya EE, Arslan M, et al. . 
Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest. 2006;24:669-676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17118776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fahmueller YN, Nagel D, Hoffmann R-T, et al. . 
Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer. 2013;132:2349-2358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23047645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sharpe AH, Pauken KE.. 
The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153-167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28990585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rizvi NA, Hellmann MD, Snyder A, et al. . 
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4993154</ArticleId>
            <ArticleId IdType="pubmed">25765070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sylman JL, Mitrugno A, Atallah M, et al. . 
The predictive value of inflammation-related peripheral blood measurements in cancer staging and prognosis. Front Oncol. 2018;8:78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5871812</ArticleId>
            <ArticleId IdType="pubmed">29619344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hashimoto M, Fujita K, Nakayama T, et al. . 
Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patients. Transl Androl Urol 2021;10:2838847-2832847.</Citation>
        </Reference>
        <Reference>
          <Citation>
Kumarasamy C, Tiwary V, Sunil K, et al. . 
Prognostic utility of platelet–lymphocyte ratio, neutrophil–lymphocyte ratio and monocyte–lymphocyte ratio in head and neck cancers: a detailed PRISMA compliant systematic review and meta-analysis. Cancers 2021;13:4166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8393748</ArticleId>
            <ArticleId IdType="pubmed">34439320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
de Wit R, Wülfing C, Castellano D, et al. . 
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study. ESMO Open 2021;6:100241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8390550</ArticleId>
            <ArticleId IdType="pubmed">34450475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Daher S, Lawrence YR, Dudnik E, et al. . 
Nivolumab in non-small cell lung cancer: real world long-term survival results and blood-based efficacy biomarkers. Front Oncol. 2021;11:2792.</Citation>
        </Reference>
        <Reference>
          <Citation>
Naik GS, Buchbinder EI, Cohen JV, et al. . 
Long-term overall survival and predictors in anti-PD-1-naive melanoma patients with brain metastases treated with immune checkpoint inhibitors in the real-world setting: a multicohort study. J Immunother Hagerstown Md 1997 2021;44:307-318.</Citation>
        </Reference>
        <Reference>
          <Citation>
Ren F, Zhao T, Liu B, et al. . 
Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB). OncoTargets Ther 2019;12:4235-4244.</Citation>
        </Reference>
        <Reference>
          <Citation>
Saravia D, Okabe N, Park W, et al. . 
Neutrophil-lymphocyte-ratio to complement the prediction ability of PD-L1 expression for outcomes in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. J Clin Oncol. 2018;36:e15102-e15102.</Citation>
        </Reference>
        <Reference>
          <Citation>
Ferrucci PF, Ascierto PA, Pigozzo J, et al. . 
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol Off J Eur Soc Med Oncol 2016;27:732-738.</Citation>
        </Reference>
        <Reference>
          <Citation>
Khan M, Zhao Z, Arooj S, et al. . 
Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy. Front Immunol. 2020;11:587460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7710690</ArticleId>
            <ArticleId IdType="pubmed">33329567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ruan Y, Hu W, Li W, et al. . 
Analysis of plasma EBV-DNA and soluble checkpoint proteins in nasopharyngeal carcinoma patients after definitive intensity-modulated radiotherapy. Biomed Res Int. 2019;2019:e3939720.</Citation>
        </Reference>
        <Reference>
          <Citation>
Sorensen SF, Demuth C, Weber B, et al. . 
Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. Lung Cancer Amst Neth 2016;100:77-84.</Citation>
        </Reference>
        <Reference>
          <Citation>
Tiako Meyo M, Jouinot A, Giroux-Leprieur E, et al. . 
Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study. Cancers 2020;12:E473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7072584</ArticleId>
            <ArticleId IdType="pubmed">32085544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bast RC, Klug TL, St John E, et al. . 
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6310399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rustin GJS, Vergote I, Eisenhauer E, et al. . 
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419-423. 10.1097/IGC.0b013e3182070f17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/IGC.0b013e3182070f17</ArticleId>
            <ArticleId IdType="pubmed">21270624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fehm T, Heller F, Krämer S, et al. . 
Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res. 2005;25:1551-1554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16033059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rustin GJS.
Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol Off J Eur Soc Med Oncol 2011;22(Suppl 8):viii45-viii48.</Citation>
        </Reference>
        <Reference>
          <Citation>
Rustin G, van der Burg M, Griffin C, et al. . 
Early versus delayed treatment of relapsed ovarian cancer. Lancet Lond Engl 2011;377:380-381.</Citation>
        </Reference>
        <Reference>
          <Citation>
Rustin GJS, van der Burg MEL, Griffin CL, et al. . 
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet Lond Engl 2010;376:1155-1163.</Citation>
        </Reference>
        <Reference>
          <Citation>
Lindemann K, Kristensen G, Mirza MR, et al. . 
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial. Ann Oncol Off J Eur Soc Med Oncol 2016;27:1505-1510.</Citation>
        </Reference>
        <Reference>
          <Citation>
Lilja H.
A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest. 1985;76:1899-1903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC424236</ArticleId>
            <ArticleId IdType="pubmed">3902893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Armstrong AJ, Garrett-Mayer E, Ou Yang Y-C, et al. . 
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25:3965-3970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17761981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lilja H, Ulmert D, Vickers AJ.. 
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268-278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18337732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moreira DM, Howard LE, Sourbeer KN, et al. . 
Predictors of time to metastasis in castration-resistant prostate cancer. Urology 2016;96:171-176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5536963</ArticleId>
            <ArticleId IdType="pubmed">27318265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smith MR, Cook R, Lee K-A, et al. . 
Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011;117:2077-2085.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3116053</ArticleId>
            <ArticleId IdType="pubmed">21523719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Halabi S, Lin C-Y, Kelly WK, et al. . 
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32:671-677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3927736</ArticleId>
            <ArticleId IdType="pubmed">24449231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Scher HI, Morris MJ, Stadler WM, et al. . 
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402-1418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4872347</ArticleId>
            <ArticleId IdType="pubmed">26903579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Conteduca V, Oromendia C, Eng KW, et al. . 
Clinical features of neuroendocrine prostate cancer. Eur J Cancer Oxf Engl 1990 2019;121:7-18.</Citation>
        </Reference>
        <Reference>
          <Citation>
Gold P, Freedman SO.. 
Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 1965;122:467-481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2138078</ArticleId>
            <ArticleId IdType="pubmed">4953873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hammarström S.
The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9:67-81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10202129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
George PK, Loewenstein MS, O’Brien MJ, et al. . 
Circulating CEA levels in patients with fulminant hepatitis. Dig Dis Sci. 1982;27:139-142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7075408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lakemeyer L, Sander S, Wittau M, et al. . 
Diagnostic and prognostic value of CEA and CA19-9 in colorectal cancer. Diseases 2021;9:21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8006010</ArticleId>
            <ArticleId IdType="pubmed">33802962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tan E, Gouvas N, Nicholls RJ, et al. . 
Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol. 2009;18:15-24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18619834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu Z, Zhang Y, Niu Y, et al. . 
A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer. PLoS One. 2014;9:e103910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4126674</ArticleId>
            <ArticleId IdType="pubmed">25105762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Su B-B, Shi H, Wan J.. 
Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World J Gastroenterol. 2012;18:2121-2126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3342612</ArticleId>
            <ArticleId IdType="pubmed">22563201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Faria SC, Sagebiel T, Patnana M, et al. . 
Tumor markers: myths and facts unfolded. Abdom Radiol NY 2019;44:1575-1600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30498924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goldstein MJ, Mitchell EP.. 
Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005;23:338-351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16100946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Iwanicki-Caron I, Di Fiore F, Roque I, et al. . 
Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 2008;26:3681-3686.</Citation>
        </Reference>
        <Reference>
          <Citation>
Scheer MGW, Sloots CEJ, van der Wilt GJ, et al. . 
Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol Off J Eur Soc Med Oncol 2008;19:1829-1835.</Citation>
        </Reference>
        <Reference>
          <Citation>
Ritts RE, Del Villano BC, Go VL, et al. . 
Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank. Int J Cancer. 1984;33:339-345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6199316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Safi F, Beger HG, Bittner R, et al. . 
CA 19-9 and pancreatic adenocarcinoma. Cancer 1986;57:779-783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3455839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tempero MA, Uchida E, Takasaki H, et al. . 
Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501-5503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3308077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wu Z, Kuntz AI, Wadleigh RG.. 
CA 19-9 tumor marker: is it reliable?
Hematol Oncol
2013;11:50-55.</Citation>
        </Reference>
        <Reference>
          <Citation>
Ballehaninna UK, Chamberlain RS.. 
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 2012;3:105-119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3397644</ArticleId>
            <ArticleId IdType="pubmed">22811878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Halm U, Schumann T, Schiefke I, et al. . 
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82:1013-1016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2374423</ArticleId>
            <ArticleId IdType="pubmed">10737382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Humphris JL, Chang DK, Johns AL, et al. . 
The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol Off J Eur Soc Med Oncol 2012;23:1713-1722.</Citation>
        </Reference>
        <Reference>
          <Citation>
O’Neill RS, Stoita A.. 
Biomarkers in the diagnosis of pancreatic cancer: are we closer to finding the golden ticket?. World J Gastroenterol. 2021;27:4045-4087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8311531</ArticleId>
            <ArticleId IdType="pubmed">34326612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ashworth TR.
A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med J Aust. 1869;14:146-147.</Citation>
        </Reference>
        <Reference>
          <Citation>
Carey RW, Taft PD, Bennett JM, et al. . 
Carcinocythemia (carcinoma cell leukemia): an acute leukemia-like picture due to metastatic carcinoma cells. Am J Med. 1976;60:273-278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1062163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Heller G, McCormack R, Kheoh T, et al. . 
Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials. J Clin Oncol Off J Am Soc Clin Oncol 2018;36:572-580.</Citation>
        </Reference>
        <Reference>
          <Citation>
Scher HI, Heller G, Molina A, et al. . 
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol. 2015;33:1348-1355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4397279</ArticleId>
            <ArticleId IdType="pubmed">25800753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Heller G, Fizazi K, McCormack R, et al. . 
The added value of circulating tumor cell enumeration to standard markers in assessing prognosis in a metastatic castration-resistant prostate cancer population. Clin Cancer Res Off J Am Assoc Cancer Res 2017;23:1967-1973. 10.1158/1078-0432.CCR-16-1224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-1224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
de Bono JS, Attard G, Adjei A, et al. . 
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res. 2007;13:3611-3616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17575225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Riethdorf S, Müller V, Zhang L, et al. . 
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010;16:2634-2645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20406831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nicolazzo C, Raimondi C, Mancini M, et al. . 
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci Rep. 2016;6:31726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4995431</ArticleId>
            <ArticleId IdType="pubmed">27553175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Williams SCP.
Circulating tumor cells. Proc Natl Acad Sci USA. 2013;110:4861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3612640</ArticleId>
            <ArticleId IdType="pubmed">23533270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mandel P, Metais P.. 
Nuclear acids in human blood plasma. C R Seances Soc Biol Fil 1948;142:241-243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18875018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Leon SA, Shapiro B, Sklaroff DM, et al. . 
Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977:646-650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">837366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sorenson GD, Pribish DM, Valone FH, et al. . 
Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 1994;3:67-71.</Citation>
        </Reference>
        <Reference>
          <Citation>
Stroun M, Anker P, Maurice P, et al. . 
Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989;46:318-322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2779946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Coombes RC, Page K, Salari R, et al. . 
Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019;25:4255-4263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30992300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu MC, Oxnard GR, Klein EA, et al. . 
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745-759.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8274402</ArticleId>
            <ArticleId IdType="pubmed">33506766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brannon AR, Jayakumaran G, Diosdado M, et al. . 
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nat Commun. 2021;12:3770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8213710</ArticleId>
            <ArticleId IdType="pubmed">34145282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rothwell DG, Ayub M, Cook N, et al. . 
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019;25:738-743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31011204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kustanovich A, Schwartz R, Peretz T, et al. . 
Life and death of circulating cell-free DNA. Cancer Biol Ther. 2019;20:1057-1067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6606043</ArticleId>
            <ArticleId IdType="pubmed">30990132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yao W, Mei C, Nan X, et al. . 
Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: a qualitative study. Gene 2016;590:142-148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27317895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Diehl F, Schmidt K, Choti MA, et al. . 
Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985-990.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2820391</ArticleId>
            <ArticleId IdType="pubmed">18670422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dawson S-J, Tsui DWY, Murtaza M, et al. . 
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199-1209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23484797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schreuer M, Meersseman G, Van Den Herrewegen S, et al. . 
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. J Transl Med. 2016;14:95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4837559</ArticleId>
            <ArticleId IdType="pubmed">27095081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Syeda MM, Wiggins JM, Corless BC, et al. . 
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncol. 2021;22:370-380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8034833</ArticleId>
            <ArticleId IdType="pubmed">33587894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Powles T, Assaf ZJ, Davarpanah N, et al. . 
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 2021;595:432-437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34135506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bratman SV, Yang SYC, Iafolla MAJ, et al. . 
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer 2020;1:873-881.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35121950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nabet BY, Esfahani MS, Moding EJ, et al. . 
Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 2020;183:363-376.e13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7572899</ArticleId>
            <ArticleId IdType="pubmed">33007267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee JH, Long GV, Menzies AM, et al. . 
Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol 2018;4:717-721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5885201</ArticleId>
            <ArticleId IdType="pubmed">29423503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang SYC, Lien SC, Wang BX, et al. . 
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nat Commun. 2021;12:5137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8390680</ArticleId>
            <ArticleId IdType="pubmed">34446728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Afrifa J, Zhao T, Yu J.. 
Circulating mitochondria DNA, a non-invasive cancer diagnostic biomarker candidate. Mitochondrion 2019;47:238-243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30562607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li L, Hann H-W, Wan S, et al. . 
Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection. Sci Rep. 2016:6. 10.1038/srep23992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep23992</ArticleId>
            <ArticleId IdType="pmc">PMC5431375</ArticleId>
            <ArticleId IdType="pubmed">28442741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Campitelli M, Jeannot E, Peter M, et al. . 
human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients. PLoS One. 2012:7. 10.1371/journal.pone.0043393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0043393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chera BS, Kumar S, Shen C, et al. . 
Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol Off J Am Soc Clin Oncol 2020;38:1050-1058.</Citation>
        </Reference>
        <Reference>
          <Citation>
Lo YMD, Chan LYS, Lo K-W, et al. . 
Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999;59:1188-1191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10096545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Valpione S, Galvani E, Tweedy J, et al. . 
Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. Nat Cancer 2020;1:210-221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7046489</ArticleId>
            <ArticleId IdType="pubmed">32110781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kolenda T, Guglas K, Baranowski D, et al. . 
cfRNAs as biomarkers in oncology – still experimental or applied tool for personalized medicine already?. Rep Pract Oncol Radiother 2020;25:783-792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7451588</ArticleId>
            <ArticleId IdType="pubmed">32904167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lawrie CH, Gal S, Dunlop HM, et al. . 
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672-675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18318758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mitchell PS, Parkin RK, Kroh EM, et al. . 
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513-10518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2492472</ArticleId>
            <ArticleId IdType="pubmed">18663219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Reddi KK, Holland JF.. 
Elevated serum ribonuclease in patients with pancreatic cancer. Proc Natl Acad Sci USA. 1976;73:2308-2310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC430542</ArticleId>
            <ArticleId IdType="pubmed">1065880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Anelli L, Zagaria A, Specchia G, et al. . 
Dysregulation of miRNA in leukemia: exploiting miRNA expression profiles as biomarkers. Int J Mol Sci. 2021:22. 10.3390/ijms22137156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22137156</ArticleId>
            <ArticleId IdType="pmc">PMC8744821</ArticleId>
            <ArticleId IdType="pubmed">35008458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Balázs K, Antal L, Sáfrány G, et al. . 
Blood-derived biomarkers of diagnosis, prognosis and therapy response in prostate cancer patients. J Pers Med 2021:11. 10.3390/jpm11040296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jpm11040296</ArticleId>
            <ArticleId IdType="pmc">PMC8781414</ArticleId>
            <ArticleId IdType="pubmed">35055326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Leao R, Albersen M, Looijenga LHJ, et al. . 
Circulating MicroRNAs, the next-generation serum biomarkers in testicular germ cell tumours: a systematic review. Eur Urol. 2021;80:456-466. 10.1016/j.eururo.2021.06.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2021.06.006</ArticleId>
            <ArticleId IdType="pubmed">34175151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ohtsuka M, Iwamoto K, Naito A, et al. . 
Circulating microRNAs in gastrointestinal cancer. Cancers 2021:13. 10.3390/cancers13133348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13133348</ArticleId>
            <ArticleId IdType="pmc">PMC8749855</ArticleId>
            <ArticleId IdType="pubmed">35008178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hansen TF, Carlsen AL, Heegaard NHH, et al. . 
Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. Br J Cancer. 2015;112:624-629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4333496</ArticleId>
            <ArticleId IdType="pubmed">25584492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Benson EA, Skaar TC, Liu Y, et al. . 
Carboplatin with decitabine therapy, in recurrent platinum resistant ovarian cancer, alters circulating miRNAs concentrations: a pilot study. PLoS One. 2015:10. 10.1371/journal.pone.0141279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0141279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Deveson IW, Gong B, Lai K, et al. . 
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nat Biotechnol. 2021:1-14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7771724</ArticleId>
            <ArticleId IdType="pubmed">33376248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Théry C, Zitvogel L, Amigorena S.. 
Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2:569-579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12154376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Aaronson S, Behrens U, Orner R, et al. . 
Ultrastructure of intracellular and extracellular vesicles, membranes, and myelin figures produced by Ochromonas danica. J Ultrastruct Res. 1971;35:418-30. 10.1016/s0022-5320(71)80003-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0022-5320(71)80003-5</ArticleId>
            <ArticleId IdType="pubmed">4111037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Berteloot A, Chabot JG, Hugon JS.. 
Turnover of mouse intestinal brush border membrane proteins and enzymes in organ culture. A direct evaluation from studies on the evolution of enzyme activities during the culture. Biochim Biophys Acta. 1981;678:423-36. 10.1016/0304-4165(81)90124-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0304-4165(81)90124-0</ArticleId>
            <ArticleId IdType="pubmed">6797477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wolfers J, Lozier A, Raposo G, et al. . 
Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001;7:297-303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11231627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lässer C, Alikhani V, Ekström K, et al. . 
Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J Transl Med. 2011. 10.1186/1479-5876-9-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1479-5876-9-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lässer C, O’Neil SE, Ekerljung L, et al. . 
RNA-containing exosomes in human nasal secretions. Am J Rhinol Allergy 2011;25:89-93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21172122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pisitkun T, Shen RF, Knepper MA.. 
Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA. 2004;101:13368-73. 10.1073/pnas.0403453101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0403453101</ArticleId>
            <ArticleId IdType="pmc">PMC516573</ArticleId>
            <ArticleId IdType="pubmed">15326289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Andre F, Schartz NE, Movassagh M, et al. . 
Malignant effusions and immunogenic tumour-derived exosomes. The Lancet 2002;360:295-305.</Citation>
        </Reference>
        <Reference>
          <Citation>
Bard M, Hegmans J, Hemmes A, et al. . 
Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol. 2004:31. 10.1165/rcmb.2003-0238OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2003-0238OC</ArticleId>
            <ArticleId IdType="pubmed">12829449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Caby M, Lankar D, Vincendeau-Scherrer C, et al. . 
Exosomal-like vesicles are present in human blood plasma. Int Immunol. 2005:17. 10.1093/intimm/dxh267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/intimm/dxh267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Taylor DD, Gercel-Taylor C.. 
MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110:13-21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18589210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Czystowska-Kuzmicz M, Whiteside TL.. 
The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer. Expert Opin Biol Ther. 2021;21:241-258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7880862</ArticleId>
            <ArticleId IdType="pubmed">32813990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yu H, Perez L, Chang Q, et al. . 
A phase 1/2 trial of ruxolitinib and erlotinib in patients with EGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 2017;12:102-109. 10.1016/j.jtho.2016.08.140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2016.08.140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tang Y, Zhang P, Wang Y, et al. . 
The biogenesis, biology, and clinical significance of exosomal PD-L1 in cancer. Front Immunol. 2020:11. 10.3389/fimmu.2020.00604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.00604</ArticleId>
            <ArticleId IdType="pmc">PMC7002388</ArticleId>
            <ArticleId IdType="pubmed">32082309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen G, Huang AC, Zhang W, et al. . 
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 2018;560:382-386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6095740</ArticleId>
            <ArticleId IdType="pubmed">30089911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cordonnier M, Nardin C, Chanteloup G, et al. . 
Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J Extracell Vesicles 2020;9:1710899.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6968537</ArticleId>
            <ArticleId IdType="pubmed">32002173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ibsen SD, Wright J, Lewis JM, et al. . 
Rapid isolation and detection of exosomes and associated biomarkers from plasma. ACS Nano. 2017;11:6641-6651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28671449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kanwar SS, Dunlay CJ, Simeone DM, et al. . 
Microfluidic device (ExoChip) for On-Chip isolation, quantification and characterization of circulating exosomes. Lab Chip. 2014;14:1891-1900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4134440</ArticleId>
            <ArticleId IdType="pubmed">24722878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhao X, Zhang W, Qiu X, et al. . 
Rapid and sensitive exosome detection with CRISPR/Cas12a. Anal Bioanal Chem. 2020;412:601-609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31897558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. . 
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18177721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Levine AJ, Puzio-Kuter AM.. 
The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010;330:1340-1344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21127244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Warburg O.
On the origin of cancer cells. Science 1956;123:309-314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13298683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhan H, Ciano K, Dong K, et al. . 
Targeting glutamine metabolism in myeloproliferative neoplasms. Blood Cells Mol Dis. 2015;55:241-247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5105231</ArticleId>
            <ArticleId IdType="pubmed">26227854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ward PS, Patel J, Wise DR, et al. . 
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225-234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2849316</ArticleId>
            <ArticleId IdType="pubmed">20171147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Beger RD.
A review of applications of metabolomics in cancer. Metabolites 2013;3:552-574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3901293</ArticleId>
            <ArticleId IdType="pubmed">24958139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wishart DS.
Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016;15:473-484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26965202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Markley JL, Brüschweiler R, Edison AS, et al. . 
The future of NMR-based metabolomics. Curr Opin Biotechnol. 2017;43:34-40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5305426</ArticleId>
            <ArticleId IdType="pubmed">27580257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhao Z, Xiao Y, Elson P, et al. . 
Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 2007;25:2696-2701.</Citation>
        </Reference>
        <Reference>
          <Citation>
Lario S, Ramírez-Lázaro MJ, Sanjuan-Herráez D, et al. . 
Plasma sample based analysis of gastric cancer progression using targeted metabolomics. Sci Rep. 2017;7:17774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5736578</ArticleId>
            <ArticleId IdType="pubmed">29259332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Loras A, Trassierra M, Sanjuan-Herráez D, et al. . 
Bladder cancer recurrence surveillance by urine metabolomics analysis. Sci Rep. 2018;8:9172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6004013</ArticleId>
            <ArticleId IdType="pubmed">29907864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang Q, Gao P, Wang X, et al. . 
The early diagnosis and monitoring of squamous cell carcinoma via saliva metabolomics. Sci Rep. 2014;4:6802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4213796</ArticleId>
            <ArticleId IdType="pubmed">25354816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Backshall A, Sharma R, Clarke SJ, et al. . 
Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin Cancer Res Off J Am Assoc Cancer Res 2011;17:3019-3028.</Citation>
        </Reference>
        <Reference>
          <Citation>
Sinha R, Ahn J, Sampson JN, et al. . 
Fecal microbiota, fecal metabolome, and colorectal cancer interrelations. PLoS One. 2016;11:e0152126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4807824</ArticleId>
            <ArticleId IdType="pubmed">27015276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Reiazi R, Abbas E, Famiyeh P, et al. . 
The impact of the variation of imaging parameters on the robustness of computed tomography radiomic features: a review. Comput Biol Med. 2021;133:104400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33930766</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
